Sight Sciences (SGHT)

• Market cap: $178M
• 1 day: -0.29%
• 5 days: -8.00%
• 1 month: -16.46%
• 3 months: 13.11%
• 6 months: 16.16%
• Year to date: -3.63%
• 1 year: -55.48%
• 5 years: -89.70%
• 10 years: -89.70%
• Sector: Healthcare
• Industry: Medical Devices

About: Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.

Employees: 216

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

4,750% more call options, than puts

Call options by funds: $97K | Put options by funds: $2K

47% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 19

4.26% less ownership

Funds ownership: 44.67% [Q4 2024] → 40.41% (-4.26%) [Q1 2025]

7% less funds holding

Funds holding: 83 [Q4 2024] → 77 (-6) [Q1 2025]

29% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 14

33% less funds holding in top 10

Funds holding in top 10: 3 [Q4 2024] → 2 (-1) [Q1 2025]

51% less capital invested

Capital invested by funds: $112M [Q4 2024] → $55.3M (-$56.8M) [Q1 2025]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $3 13% downside
• Avg. target: $3.65 6% upside
• High target: $4 16% upside

4 analyst ratings

• positive: 0 0%
• neutral: 4 100%
• negative: 0 0%

Morgan Stanley Cecilia Furlong	16% upside $4	Equal-Weight Maintained	15 Jul 2025
Piper Sandler Adam Maeder	16% upside $4	Neutral Maintained	18 Jun 2025
Citigroup Joanne Wuensch	4% upside $3.60	Neutral Maintained	22 May 2025
Lake Street Frank Takkinen	13% downside $3	Hold Maintained	9 May 2025